News

Law

Asset Management

Investment Banking

Wealth

Hedge Funds

People

Newsletters

Events

Lists

JP Morgan banker faces another bitter pill as AbbVie mulls $50bn reverse

AbbVie may decide to scrap its planned $56.1 billion deal for UK drugmaker Shire after a US crackdown on so-called inversion deals

One of JP Morgan’s top investment bankers in London is facing fresh multibillion-dollar disappointment as his client decides whether to pull the plug on a $50 billion-plus deal.

Laurence Hollingworth, JP Morgan's head of industry coverage for corporates in Europe, the Middle East and Africa, is one of three London-based bankers advising pharmaceuticals giant AbbVie on its proposed $56.1 billion takeover of the UK drugmaker Shire.

WSJ Logo